+33 1 76 70 47 90
/
creativ@creativ-ceutical.com
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
[P.3.d.011] Reasons for aripiprazole discontinuation: a retrospective review
Home
Publications
[P.3.d.011] Reasons for aripiprazole discontinuation: a retrospective review
Back Home
[P.3.d.011] Reasons for aripiprazole discontinuation: a retrospective review
2013 European Neuropsychopharmacology
Millier, A. | Briquet, B. | Cadi-Soussi, N. | Murthy, V. | Toumi, M. |
Volume: 23, Supplement 2, Issue: 0, Pages: S464,
aripiprazole, database analysis, drug compliance, Retrospective Studies, Schizophrenia,
https://www.doi.org/http://dx.doi.org/10.1016/S0924-977X(13)70734-X
